EHS
EHS

A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer.

Related Articles

A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer.

Clin Cancer Res. 2018 Jul 18;:

Authors: Ponath P, Menezes DL, Pan C, Chen B, Oyasu M, Strachan D, LeBlanc H, Sun H, Wang XT, Rangan V, Deshpande S, Cristea S, Park KS, Sage J, Cardarelli PM

Abstract
PURPOSE: The ganglioside fucosyl-GM1 (FucGM1) is a tumor-associated antigen expressed in a large percentage of human small cell lung cancer (SCLC) tumors, but absent in most normal adult tissues, making it a promising target in immuno-oncology. This study was undertaken to evaluate the preclinical efficacy of BMS-986012, a novel, nonfucosylated, fully human IgG1 antibody that binds specifically to FucGM1.
EXPERIMENTAL DESIGN: The antitumor activity of BMS-986012 was evaluated in in vitro assays using SCLC cells and in mouse xenograft and syngeneic tumor models, with and without chemotherapeutic agents and checkpoint inhibitors.
RESULTS: BMS-986012 showed high binding affinity for FcγRIIIa, which resulted in enhanced antibody-dependent cellular cytotoxicity against FucGM1-expressing tumor cells. BMS-986012-mediated tumor cell killing was also observed in complement-dependent cytotoxicity and antibody-dependent cellular phagocytosis assays. In mouse SCLC models, BMS-986012 demonstrated efficacy and was well tolerated. In the DMS79 xenograft model, tumor regression was achieved with BMS-986012 doses of 0.3 mg/kg and greater; antitumor activity was enhanced when BMS-986012 was combined with standard-of-care cisplatin or etoposide. In a syngeneic model, tumors derived from a genetically engineered model of SCLC were treated with BMS-986012 or anti-FucGM1 with a mouse IgG2a Fc and their responses evaluated; when BMS-986012 was combined with anti-PD-1 or anti-CD137 antibody, responses significantly improved.
CONCLUSIONS: Single agent BMS-986012 demonstrated robust antitumor activity, with the addition of chemotherapeutic or immunomodulatory agents further inhibiting SCLC growth in the same models. These preclinical data supported evaluation of BMS-986012 in a phase 1 clinical trial of patients with relapsed, refractory SCLC.

PMID: 30021910 [PubMed – as supplied by publisher]

EHS
Back to top button